NUS Links:
Summary
The combination of chemotherapy (or targeted therapy) with immunotherapy is emerging rapidly as a promising strategy in the first line treatment against several tumor types. This study led by Dr Raghav Sundar provides the basis to further optimise treatment options for first-line metastatic GEAC patients using combination of Immunotherapy and chemotherapy.
Link to article: https://bit.ly/35WzvHy
We are pleased to share that Prof. Goh Boon Cher and A/Prof. Wang Lingzhi have published a new edited volume …
Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This resistance is linked …
Treatment of relapsed/refractory non-Hodgkin’s lymphoma (R/R-NHL) remains one of the most difficult challenges in haematologic malignancies, with many patients exhausting …